AMR innovation inspired by nature
We transformphage technologyto deliver the next generation of precision medicine.
By 2050, AMR could claim over 50 million lives every year unless we act now.
"Despite this critical need, it’s been >35 years since the last new class of antibiotics hit the market. The clock is ticking—it’s time to revitalize the pipeline with innovative, precision-targeted antimicrobial drugs.
A targeted approach to addressing antibiotic resistance
Amid growing global concerns over antibiotic resistance, PhalconBio is advancing the next generation of antibacterial precision medicines. These targeted therapies are designed to revolutionize patient care, offering a sustainable and innovative alternative to traditional antibiotics. PhalconBio's technology platform transforms conventional phage therapy by enhancing its efficacy, reducing the emergence of drug resistance, while maintaining drug specificity. The result: highly effective and safe new medicines that set a new standard in antibacterial treatment.
Phage Therapy
Bacteriophages (or phages), are viral predators that specifically infect and kill bacteria, making them a powerful tool for treating bacterial infections. Unlike broad-spectrum antibiotics, phages target specific pathogenic bacterial species, minimizing harm to beneficial bacteria and reducing the risk of disrupting the microbiome. Phages are a safe and promising solution to combat drug-resistant infections. At PhalconBio, we improve and functionalize phage therapies through targeted engineering.
PhalconBio's Engineered Phage Therapeutics (EPTs)
PhalconBio’s EPTs are genetically enhanced bacteriophages that integrate precision targeting with phage-mediated delivery of antibacterial effector proteins. These engineered phages not only seek out and eliminate pathogenic bacteria but also reprogram them to produce secondary precision antimicrobials directly at the site of infection. This innovative, highly targeted approach mediates a two-pronged attack:
• Improve antibacterial efficacy
• Minimize resistance development
• Improve biofilm targeting
PhalconBio's proprietary EPT platform technology has been developed in close collaborations with our partners at ETH Zurich and builds on > 10 years of engineering research.
EPT landmark study published by PhalconBio Scientists: (link)
Our lead program: Targeting pulmonary Pseudomonas aeruginosa infections
Pseudomonas aeruginosa is a highly adaptable opportunistic pathogen known for causing severe disease, including pneumonia, bloodstream infections, and wound infections. Renowned for its intrinsic antibiotic resistance and ability to form biofilms, P. aeruginosa poses a significant challenge in clinical settings, making it a critical target in the fight against antimicrobial resistance. Our lead program focuses on pulmonary P. aeruginosa infections, which are typically associated with chronic structural lung diseases including bronchiectasis, cystic fibrosis, primary ciliary dyskinesia as well as acute hospital-acquired or ventilator-associated pneumonia.
Our platform technology is adaptable to other ESKAPEE pathogens.
PhalconBio Featured News
This is where we share exciting developments and press releases. Stay tuned for more updates!
Management
Combining technology leadership and creativity to address areas of critical unmet medical need.
Sam is a seasoned molecular virologist with over 15 years of experience in academic and industry R&D. His expertise lies in applied phage research, with a particular focus on harnessing cutting-edge phage engineering to enhance patient care and combat the global antimicrobial resistance (AMR) crisis. Before founding PhalconBio, Sam played a pivotal role in developing much of the company’s foundational technology. He honed his skills as a group leader at ETH Zurich and later as Research Director at Micreos Pharmaceuticals, where he advanced innovative phage-based therapeutics.
Advisors
Prof. Martin Loessner is a leading microbiologist in bacteriophage research, particularly in the context of phage therapy and food safety. Based at ETH Zurich, where he heads the Laboratory of Food Microbiology, Prof. Loessner has dedicated his career to understanding the interactions between phages and bacterial pathogens. He has pioneered the development of phage-based technologies for applications in food safety, diagnostics, and therapeutic interventions. His ground-breaking research has contributed to the advancement of phage therapy as a viable alternative to antibiotics. Prof. Loessner’s work is highly regarded for its translational potential, bridging fundamental phage biology with innovative, real-world applications.
Prof. Harms heads the Laboratory of Molecular Phage Biology at ETH Zurich where he studies the biology of bacteriophages and applies this knowledge to improve antimicrobial therapies and to build biotechnology tools for the life science industry. With his extensive expertise in Pseudomonas phage-host interactions, Alexander supports the advancement of PhalconBio's lead program.
Partnerships
Connect with PhalconBio
contact@phalconbio.com
+41 78 619 02 99
PhalconBio GmbH
Zugerstrasse 76
8820 Wädenswil
Switzerland
